The sale provides MacroGenics with significant non-dilutive capital to extend its cash runway and focus on its clinical pipeline. Monitor closing conditions (regulatory and landlord consents) and any updates on pipeline catalysts. The transaction removes a capital-intensive CDMO operation, improving operational focus and financial flexibility.
MGNX drugs
MGNX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $3.52entry
- T+1 · 6mo ago −1.99%α −2.56% · $3.45
- T+5 · 6mo ago +23.58%α +23.50% · $4.35
- T+20 · 5mo ago +9.94%α +11.67% · $3.87
- T+60 · 3mo ago +13.92%α +9.54% · $4.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MacroGenics entered into a definitive agreement to sell its GMP manufacturing operations (CDMO business) to Bora Pharmaceuticals for a $122.5 million upfront cash payment, subject to customary closing adjustments and up to $5 million in contingent milestones. The transaction, expected to close in Q3 2026, provides non-dilutive capital to fund the company's R&D pipeline while retaining manufacturing access via a supply agreement.
Key Financial Metrics
Key Facts
- Base purchase price of $122.5 million in cash at closing, subject to working capital and indebtedness adjustments.
- Up to $5 million in additional contingent payments based on manufacturing milestones through 2028.
- Transaction includes transfer of the Rockville, MD manufacturing facility (11,000L capacity) and Frederick, MD warehouse.
- Approximately 140 MacroGenics employees expected to be hired by Bora.
- Closing expected in the third quarter of 2026, subject to customary conditions including landlord consents and regulatory approvals.
- MacroGenics will enter into a manufacturing and supply agreement with Bora for clinical and commercial supply post-closing.
- Transaction approved by both companies' boards of directors.
Financial Impact
Upfront cash consideration of $122.5 million, equating to ~65% of MacroGenics' pre-announcement market cap of $188 million. Potential additional $5 million in contingent payments.
Risk Factors
- Risk that closing conditions (including required consents) may not be satisfied, delaying or preventing the transaction.
- Potential for lower-than-expected net proceeds after transaction fees and working capital adjustments.
- Contingent earnout may not be realized, capping additional upside at $5 million.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000035 |
| Exhibit: exhibit991_pressrelease.htm | 0001125345-26-000035 |
| Document: mgnx-20260511.htm | 0001125345-26-000035 |
| Document: 0001125345-26-000035-index-headers.html | 0001125345-26-000035 |
| Document: 0001125345-26-000035-index.html | 0001125345-26-000035 |
| Document: 0001125345-26-000035.txt | 0001125345-26-000035 |
Track record
21 reports on MGNX
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers